国内创新药行业再次迎来利好政策!近日,国家药监局发布《关于优化创新药临床试验审评审批有关事项的公告》,明确提出对符合要求的创新药临床试验申请设立“30日审评审批通道”。在利好政策的支持下,我国创新药研发将进一步提速。机构指出,下一代IO、减重、小核酸、Protac、KRAS、TCE、自免双抗等七个创新药赛道市场空间巨大,目前正在发生着积极变化,或在短期内有望迎来价值拐点。下一代IO(免疫疗法)主要...
Source Link国内创新药行业再次迎来利好政策!近日,国家药监局发布《关于优化创新药临床试验审评审批有关事项的公告》,明确提出对符合要求的创新药临床试验申请设立“30日审评审批通道”。在利好政策的支持下,我国创新药研发将进一步提速。机构指出,下一代IO、减重、小核酸、Protac、KRAS、TCE、自免双抗等七个创新药赛道市场空间巨大,目前正在发生着积极变化,或在短期内有望迎来价值拐点。下一代IO(免疫疗法)主要...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.